Difference between revisions of "REM-NM FT Evaluation"

From IHE Wiki
Jump to navigation Jump to search
Line 32: Line 32:
 
   ATHON srl                                                      DSS/OF
 
   ATHON srl                                                      DSS/OF
 
   Bayer Healthcare              DIC, DIR, DR                       DIR, DR
 
   Bayer Healthcare              DIC, DIR, DR                       DIR, DR
   Canon Medical Systems                                          MOD
+
   Canon Medical Systems        MOD                               MOD
 
   GE Precision Healthcare LLC  DR              RAS, DIC, DIR, DR  RAS, DIC, DIR, DR
 
   GE Precision Healthcare LLC  DR              RAS, DIC, DIR, DR  RAS, DIC, DIR, DR
 
   J4Care GmbH                  IM                                  
 
   J4Care GmbH                  IM                                  
Line 38: Line 38:
 
   Philips Medical Systems                     DSS/OF               
 
   Philips Medical Systems                     DSS/OF               
 
   Tiani \"Spirit\" GmbH        IM                                 IM
 
   Tiani \"Spirit\" GmbH        IM                                 IM
  Toshiba Medical Systems      MOD                                 
+
                   
 
 
* Has the profile been successfully tested with all actors at least at one Connectathon?
 
* Has the profile been successfully tested with all actors at least at one Connectathon?
 
::* Yes, see above
 
::* Yes, see above

Revision as of 15:40, 8 February 2023

Proposal

Radiation Exposure Monitoring for Nuclear Medicine (REM-NM) has been nominated for advancement to Final Text. (Advocate: Steve Nichols) Per the Final Text Process, Items in blue text below warrant Committee discussion.

Technical Committee Checklist

  • Are all significant CPs against the profile "closed"
  • CP-RAD-372
  • Are all significant CPs against the underlying standards "closed"?
  • No CPs indicated in trial implementation
  • Have all significant comments been CP'd or rejected?
  • CP-RAD-372 is still open
  • Have all open issues listed in the Supplement been closed?
  • Yes
  • Have all significant issues at Connectathon been dealt with?
  • TBD
  • Has the Connectathon Project Manager been queried and significant issues addressed?
  • TBD

Technical Committee Consensus

  • TBD

Planning Committee Checklist

  • Has the profile been through a Connectathon in at least two regions?
  • Yes
                               Eur. 2017       NA 2020             Eur./NA 2022
 ----------------------------- --------------- ------------------- -------------------
 ATHON srl                                                         DSS/OF
 Bayer Healthcare              DIC, DIR, DR                        DIR, DR
 Canon Medical Systems         MOD                                 MOD
 GE Precision Healthcare LLC   DR              RAS, DIC, DIR, DR   RAS, DIC, DIR, DR
 J4Care GmbH                   IM                                   
 Numa, Inc.                    RAS                                  
 Philips Medical Systems                       DSS/OF               
 Tiani \"Spirit\" GmbH         IM                                  IM
                 
  • Has the profile been successfully tested with all actors at least at one Connectathon?
  • Yes, see above
  • Have different implementations of each actor in the profile been tested?
  • Yes
  • Have all the options been tested successfully at at least one Connectathon?
  • NA
  • Are there IHE-provided software testing tools to address all aspects of the profile?
  • EVS DICOM validators
  • Have the standards underlying the profile been implemented? In similar use cases? In healthcare? In general IT?
  • Yes
  • (Do you have concrete reason to believe that this works robustly in the Real World) / (Are any products available for purchase that implement the profile?)
  • TBD
  • Have all issues that may have been raised about the profile been resolved?
  • TBD